Ares Trading S.A. (an affiliate of Merck KGaA), Eysins, Switzerland.
Department of Child Health, The Netherlands Organization for Applied Scientific Research TNO, Leiden, Netherlands.
Front Endocrinol (Lausanne). 2022 Jun 30;13:882192. doi: 10.3389/fendo.2022.882192. eCollection 2022.
Digital health has seen rapid advancements over the last few years in helping patients and their healthcare professionals better manage treatment for a variety of illnesses, including growth hormone (GH) therapy for growth disorders in children and adolescents. For children and adolescents requiring such therapy, as well as for their parents, the treatment is longitudinal and often involves daily injections plus close progress monitoring; a sometimes daunting task when young children are involved. Here, we describe our experience in offering devices and digital health tools to support GH therapy across some 40 countries. We also discuss how this ecosystem of care has evolved over the years based on learnings and advances in technology. Finally, we offer a glimpse of future planned enhancements and directions for digital health to play a bigger role in better managing conditions treated with GH therapy, as well as model development for adherence prediction. The continued aim of these technologies is to improve clinical decision making and support for GH-treated patients, leading to better outcomes.
在过去的几年中,数字健康在帮助患者及其医疗保健专业人员更好地管理各种疾病的治疗方面取得了快速进展,包括儿童和青少年生长障碍的生长激素 (GH) 治疗。对于需要这种治疗的儿童和青少年,以及他们的父母来说,治疗是长期的,通常涉及每天注射和密切的进展监测;当涉及到年幼的孩子时,这是一项有时令人生畏的任务。在这里,我们描述了我们在大约 40 个国家提供设备和数字健康工具以支持 GH 治疗的经验。我们还讨论了随着技术的发展和学习,这种护理生态系统多年来是如何演变的。最后,我们展望了未来计划的增强功能和方向,以便数字健康在更好地管理接受 GH 治疗的疾病以及开发依从性预测模型方面发挥更大的作用。这些技术的持续目标是改善临床决策和对接受 GH 治疗的患者的支持,从而带来更好的结果。